Literature DB >> 11678454

CTLA-4 gene polymorphism in promoter and exon-1 regions in Chinese patients with systemic lupus erythematosus.

M F Liu1, C R Wang, L C Lin, C R Wu.   

Abstract

Cytotoxic T lymphocyte associated antigen 4 (CTLA-4), a structural homologue of CD28, has been reported to be an important negative regulator of autoimmune diseases. Recent studies showed that CTLA-4 gene polymorphism was associated with several kinds of human autoimmune diseases, suggesting that CTLA-4 gene is probably a general susceptibility gene to autoimmune disease. The present study was conducted in Chinese to determine whether there is any association of the CTLA-4 gene polymorphism with the development of systemic lupus erythematosus (SLE). CTLA-4 gene polymorphism in promoter and exon 1 was detected by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) method in 81 patients with SLE and 81 normal controls. The results showed that there were no statistically significant differences in both exon 1 and promoter gene polymorphism between SLE patients and normal controls. The preliminary study does not suggest an association of the known polymorphism in exon 1 and promoter of CTLA-4 gene with Chinese SLE. However, SLE is a very heterogeneous syndrome and CTLA-4 gene polymorphism might correlate with some specific clinical features. To exploring this possibility, subgroup analysis in more patients needs to be performed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11678454     DOI: 10.1191/096120301682430249

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  9 in total

1.  CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis.

Authors:  Young Ho Lee; John B Harley; Swapan K Nath
Journal:  Hum Genet       Date:  2005-02-02       Impact factor: 4.132

2.  Association between CTLA-4 exon-1 +49A/G polymorphism and systemic lupus erythematosus: an updated analysis.

Authors:  Wei-Wei Chang; Liu Zhang; Ying-Shui Yao; Hong Su
Journal:  Mol Biol Rep       Date:  2012-06-21       Impact factor: 2.316

3.  Associations of the PTPN22 and CTLA-4 genetic polymorphisms with Taiwanese ankylosing spondylitis.

Authors:  Chun-Huang Huang; James Cheng-Chung Wei; Chun-Chieh Chen; Chih-Shien Chuang; Chia-Hsuan Chou; Yu-Jie Lin; Ming-Fuu Wang; Ruey-Hong Wong
Journal:  Rheumatol Int       Date:  2013-11-09       Impact factor: 2.631

4.  Overexpression and secretion of the soluble CTLA-4 splice variant in various autoimmune diseases and in cases with overlapping autoimmunity.

Authors:  Suad AlFadhli
Journal:  Genet Test Mol Biomarkers       Date:  2013-02-28

5.  CTLA-4 polymorphisms and systemic lupus erythematosus: a comprehensive meta-analysis.

Authors:  Jie Liu; Hong-Xin Zhang
Journal:  Genet Test Mol Biomarkers       Date:  2013-01-05

6.  CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis.

Authors:  Jin-Xia Zhai; Li-Wei Zou; Zhao-Xiang Zhang; Wen-Jing Fan; Han-Yong Wang; Ting Liu; Zheng Ren; Rui-Xue Dai; Dongqing Ye
Journal:  Mol Biol Rep       Date:  2013-08-07       Impact factor: 2.316

7.  Clinical manifestations and analyses of the cytotoxic T-lymphocyte associated-4 gene in two Japanese families with systemic lupus erythematosus.

Authors:  Keisuke Sugimoto; Shinsuke Fujita; Hidehiko Yanagida; Yoshihiro Shimada; Nobutada Tabata; Kazuro Yagi; Mitsuru Okada; Tsukasa Takemura
Journal:  Clin Exp Nephrol       Date:  2008-01-09       Impact factor: 2.801

8.  CTLA-4 gene polymorphism and the risk of systemic lupus erythematosus in the Chinese population.

Authors:  Ahmad Taha Khalaf; Ji-Quan Song; Ting-Ting Gao; Xiang-Ping Yu; Tie-Chi Lei
Journal:  J Biomed Biotechnol       Date:  2011-09-11

9.  Distribution of Cytotoxic T Lymphocyte-Associated Antigen-4 Promoter Polymorphisms in Taiwanese Patients with Type 2 Diabetes Mellitus.

Authors:  Yung-Luen Shih; Hsu-Feng Lu; Chiao-Wan Hsiao; Kuo-Ting Ho; Pei-Chi Chen; Chien-Ning Huang; Yuanmay Chang; Shang-Jyh Kao; Ming-Yuh Shiau; Yih-Hsin Chang
Journal:  Int J Med Sci       Date:  2018-02-12       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.